Martha Morrell's most recent trade in NeuroPace Inc was a trade of 1,338 Common Stock done at an average price of $13.5 . Disclosure was reported to the exchange on June 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.54 per share. | 03 Jun 2025 | 1,338 | 85,943 | - | 13.5 | 18,117 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.66 per share. | 27 May 2025 | 357 | 87,281 | - | 12.7 | 4,520 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.99 per share. | 20 May 2025 | 3,051 | 87,638 | - | 18.0 | 54,887 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.94 per share. | 22 Apr 2025 | 237 | 90,689 | - | 10.9 | 2,593 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2025 | 19,850 | 19,850 | - | - | Stock Option (Right to Buy) | |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2025 | 11,700 | 90,926 | - | 0 | Common Stock | |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.81 per share. | 03 Mar 2025 | 1,337 | 79,226 | - | 11.8 | 15,790 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.56 per share. | 27 Feb 2025 | 1,430 | 80,563 | - | 12.6 | 17,961 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 13.72 per share. | 21 Feb 2025 | 78,334 | 81,993 | - | 13.7 | 1,074,844 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 40,000 | 180,449 | - | - | Stock Option (Rt to Buy) | |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 21 Feb 2025 | 40,000 | 96,480 | - | 0.0 | 1,040 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.50 per share. | 21 Feb 2025 | 12,474 | 62,602 | - | 17.5 | 218,295 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 12,234 | 12,234 | - | - | Stock Option (Rt to Buy) | |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 21 Feb 2025 | 12,234 | 56,480 | - | 0.0 | 318 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 21 Feb 2025 | 5,167 | 79,941 | - | 4.1 | 21,185 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.23 per share. | 21 Feb 2025 | 3,405 | 43,670 | - | 14.2 | 48,453 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.98 per share. | 21 Feb 2025 | 3,045 | 57,986 | - | 8.0 | 24,299 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.24 per share. | 21 Feb 2025 | 3,045 | 53,369 | - | 7.2 | 22,046 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.19 per share. | 21 Feb 2025 | 3,045 | 48,753 | - | 9.2 | 27,984 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.93 per share. | 21 Feb 2025 | 1,413 | 47,340 | - | 11.9 | 16,857 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.46 per share. | 21 Feb 2025 | 1,335 | 56,511 | - | 6.5 | 8,624 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.99 per share. | 21 Feb 2025 | 1,334 | 61,031 | - | 16.0 | 21,331 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.39 per share. | 21 Feb 2025 | 1,334 | 52,035 | - | 7.4 | 9,858 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.11 per share. | 21 Feb 2025 | 1,303 | 78,407 | - | 4.1 | 5,355 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.90 per share. | 21 Feb 2025 | 1,303 | 75,340 | - | 8.9 | 11,597 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.93 per share. | 21 Feb 2025 | 1,302 | 76,874 | - | 8.9 | 11,627 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.32 per share. | 21 Feb 2025 | 926 | 85,836 | - | 8.3 | 7,704 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.04 per share. | 21 Feb 2025 | 265 | 47,075 | - | 14.0 | 3,721 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.98 per share. | 21 Feb 2025 | 264 | 85,108 | - | 3.0 | 787 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.84 per share. | 21 Feb 2025 | 264 | 75,076 | - | 14.8 | 3,918 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.00 per share. | 21 Feb 2025 | 237 | 61,268 | - | 14 | 3,318 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.65 per share. | 21 Feb 2025 | 237 | 56,414 | - | 7.6 | 1,813 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.00 per share. | 21 Feb 2025 | 237 | 51,798 | - | 6 | 1,422 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.02 per share. | 21 Feb 2025 | 233 | 85,372 | - | 3.0 | 704 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.55 per share. | 21 Feb 2025 | 231 | 85,605 | - | 5.5 | 1,282 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.25 per share. | 21 Feb 2025 | 231 | 79,710 | - | 4.3 | 982 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.13 per share. | 21 Feb 2025 | 231 | 78,176 | - | 4.1 | 954 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.88 per share. | 21 Feb 2025 | 231 | 76,643 | - | 6.9 | 1,589 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 192 | 0 | - | - | Stock Option (Rt to Buy) | |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 192 | 192 | - | - | Stock Option (Rt to Buy) | |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 21 Feb 2025 | 192 | 43,862 | - | 0.0 | 5 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 21 Feb 2025 | 192 | 44,054 | - | 0.0 | 5 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 21 Feb 2025 | 192 | 44,246 | - | 0.0 | 5 | Common stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 192 | 0 | - | - | Stock Option (Rt to Buy) | |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 29 Jan 2025 | 200 | 86,762 | - | 15 | 3,000 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 29 Jan 2025 | 100 | 86,962 | - | 15 | 1,500 | Common Stock |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.01 per share. | 24 Jan 2025 | 3,200 | 87,062 | - | 15.0 | 48,032 | Common Stock |
| NeuroPace Inc | Martha Morrell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 24,950 | 24,950 | - | - | Stock Option (Right to Buy) | |
| NeuroPace Inc | Martha Morrell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 12,500 | 90,262 | - | 0 | Common Stock | |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 50,000 | 140,449 | - | - | Stock Option (Rt to Buy) | |
| NeuroPace Inc | Martha Morrell | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 12 Feb 2024 | 50,000 | 160,327 | - | 0.0 | 1,300 | Common Stock |
| NeuroPace Inc | Martha Morrell | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.07 per share. | 02 Feb 2024 | 14,143 | 81,208 | - | 15.1 | 213,122 | Common Stock |
| NeuroPace Inc | Martha Morrell | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.17 per share. | 02 Feb 2024 | 3,446 | 77,762 | - | 15.2 | 52,278 | Common Stock |
| NeuroPace Inc | Morrell Martha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.10 per share. | 30 Jan 2024 | 11,262 | 97,937 | - | 15.1 | 170,004 | Common Stock |
| NeuroPace Inc | Morrell Martha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.08 per share. | 30 Jan 2024 | 1,923 | 96,014 | - | 15.1 | 28,990 | Common Stock |
| NeuroPace Inc | Morrell Martha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.04 per share. | 30 Jan 2024 | 663 | 95,351 | - | 15.0 | 9,971 | Common Stock |
| NeuroPace Inc | Morrell Martha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.03 per share. | 24 Jan 2024 | 827 | 109,200 | - | 15.0 | 12,426 | Common Stock |
| NeuroPace Inc | Morrell Martha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 24 Jan 2024 | 1 | 109,199 | - | 15 | 15 | Common Stock |
| NeuroPace Inc | Morrell Martha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.12 per share. | 26 Dec 2023 | 13,300 | 110,027 | - | 10.1 | 134,648 | Common Stock |
| NeuroPace Inc | Martha Morrell | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 26 Dec 2023 | 102 | 123,327 | - | 10 | 1,020 | Common Stock |
| NeuroPace Inc | Morrell Martha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.14 per share. | 20 Dec 2023 | 2,730 | 123,429 | - | 10.1 | 27,695 | Common Stock |
| NeuroPace Inc | Martha Morrell | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.16 per share. | 06 Dec 2023 | 11,005 | 126,159 | - | 8.2 | 89,773 | Common Stock |
| NeuroPace Inc | Martha Morrell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2023 | 80,000 | 137,164 | - | 0 | Common Stock | |
| NeuroPace Inc | Martha Morrell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 07 Oct 2022 | 384 | 57,164 | - | 0.0 | 10 | Common Stock |
| NeuroPace Inc | Martha Morrell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2022 | 384 | 0 | - | - | Stock Option (Right to Buy) | |
| NeuroPace Inc | Martha Morrell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2022 | 192 | 0 | - | - | Stock Option (Right to Buy) | |
| NeuroPace Inc | Martha Morrell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 07 Oct 2022 | 192 | 56,780 | - | 0.0 | 5 | Common Stock |
| NeuroPace Inc | Martha Morrell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 93,530 | 93,530 | - | - | Stock Option (Right to Buy) | |
| NeuroPace Inc | Martha Morrell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 46,760 | 56,588 | - | 0 | Common Stock | |
| NeuroPace Inc | Martha Morrell | Chief Medical officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 16,620 | 16,620 | - | - | Stock Option (Right to Buy) | |
| NeuroPace Inc | Martha Morrell | Chief Medical officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 8,310 | 9,828 | - | 0 | Common Stock |